Diabetic macular edema (DME) is an eye condition that can lead to vision loss in people with diabetes. It occurs as a result of diabetic retinopathy — damaged blood vessels in the eyes due to elevated ...

The optic cup and macula of a 24-year-old female. Image is released to Wikimedia commons with patient consent. Imaged with a non-mydriatic fundus camera at Pacific University College of Optometry.

European Commission grants marketing approval for Eylea 8 mg to treat macular edema following RVO, including branch, central and hemiretinal vein occlusion: Berlin Monday, January ...

Diabetic eye disease is a leading cause of vision loss in individuals aged 20 to 74,(3) and diabetic macular edema (DME), left untreated, is the leading cause of blindness in diabetic patients. The ...

FDA has announced it has approved Lucentis (ranibizumab injection) for the treatment of diabetic macular edema, according to a news release. DME is a sight-threatening eye disease that occurs in ...

Diabetic macular edema (DME) occurs when fluid accumulates behind the macula, the part of your retina that processes central vision. DME can occur at any stage of diabetic retinopathy (DR). However, ...

Patients with diabetic macular edema could be treated with brolucizumab with as much effectiveness as aflibercept. There were no clinically meaningful differences in visual outcomes when patients with ...

Fluocinolone implants can slow diabetic retinopathy and delay proliferation in patients with diabetic macular edema, researchers say. Compared with antivascular endothelial growth factor (anti-VEGF) ...

Please provide your email address to receive an email when new articles are posted on . One specialist highlighted cases in which systemic treatments, such as corticosteroids, are better. Another ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. UBX1325 met safety and efficacy endpoints at 24 weeks in ...

LONDON--(BUSINESS WIRE)--The global diabetic macular edema treatment market 2018-2022 is expected to post a CAGR of more than 1% during the forecast period, according to the latest market research ...

Clearside Biomedical, Inc. announced that the Chinese Center for Drug Evaluation has accepted Arctic Vision's New Drug Application (NDA) for ARCATUS®, a treatment for uveitic macular edema (UME), for ...